Correction (DOI:10.1016/j.clpt.2005.12.302);Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: First case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2

Clinical Pharmacology and Therapeutics

Volumn 79, Issue 4, 2006, Pages 389-396

  Tsuruoka, Shuichi ^a   Ioka, Takashi ^a   Wakaumi, Michi ^a   Sakamoto, Koh ichi ^a   Ookami, Hitoshi ^a   Fujimura, Akio ^a  

^a Department of Pharmacy   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC CATION TRANSPORTER 2; PILSICAINIDE; ANTIARRHYTHMIC AGENT; CATION TRANSPORT PROTEIN; DRUG DERIVATIVE; GLYCOPROTEIN P; HISTAMINE H1 RECEPTOR ANTAGONIST; LIDOCAINE;

AGED; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; FAINTNESS; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; KIDNEY CLEARANCE; KIDNEY FAILURE; MALE; MICROINJECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN TRANSPORT; QRS COMPLEX; QT PROLONGATION; SINGLE DRUG DOSE; SINUS BRADYCARDIA; SKIN ALLERGY; ADULT; ANIMAL; CHEMICALLY INDUCED DISORDER; CLINICAL OBSERVATION; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIAGNOSIS; DOUBLE BLIND PROCEDURE; DRUG INTERACTION; GENETICS; METABOLISM; OOCYTE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; XENOPUS;

ADMINISTRATION, ORAL; ADULT; AGED; ANIMALS; ANTI-ARRHYTHMIA AGENTS; AREA UNDER CURVE; ARRHYTHMIA; CATION TRANSPORT PROTEINS; CETIRIZINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LIDOCAINE; MALE; OOCYTES; P-GLYCOPROTEIN; RENAL INSUFFICIENCY; XENOPUS;

EID: 33646094207     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.09.014     Document Type: Erratum

References (23)

1. Coulie P., Delaere A., De Vos C., Donnelly F., and Rihoux J.P. Non-sedating antihistamines and cardiac arrhythmias [letter]. Lancet 351 (1998) 451
2. Woosley R.L. Cardiac actions of antihistamines. Annu Rev Pharmacol Toxicol 36 (1996) 233-252
3. Hey J.A., del Prado M., Sherwood J., Kreutner W., and Egan R.W. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittelforschung 46 (1996) 153-158
4. Atarashi H., Inoue H., Hiejima K., Hayakawa H., and The PSTAF Investigators. Conversion of recent-onset atrial fibrillation by a single oral dose of pilsicainide (Pilsicainide Suppression Trial on Atrial Fibrillation). Am J Cardiol 78 (1996) 694-697
5. Shiga T., Hashiguchi M., Urae A., Kasanuki H., and Rikihisa T. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ther 67 (2000) 222-228
6. Matzke G.R., Yeh J., Awni W.M., Halstenson C.E., and Chung M. Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. Ann Allergy 59 Pt 2 (1987) 25-30
7. Takabatake T., Ohta H., Yamamoto Y., Ishida Y., Hara H., Ushiogi Y., et al. Pharmacokinetics of SUN 1165, a new antiarrhythmic agent, in renal dysfunction. Eur J Clin Pharmacol 40 (1991) 411-414
8. Macek J., Ptacek P., and Klima J. Determination of cetirizine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 736 (1999) 231-235
9. Ueda K., Cornwell M., Gottesman M., Pastan I., Roninson I.B., Ling V., et al. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 141 (1986) 956-962
10. Taguchi Y., Kino K., Morishima M., Komano T., Kane S., and Ueda K. Alteration of substrate specificity by mutation at the His61 position in predicted transmembrane domain 1 of human MDR-1/P-glycoprotein. Biochemistry 36 (1997) 8883-8889
11. Tsuruoka S., Sugimoto K.I., Ueda K., Suzuki M., Imai M., and Fujimura A. Removal of digoxin and doxorubicin by multidrug resistance protein-overexpressed cell culture in hollow fiber. Kidney Int 56 (1999) 154-163
12. Gorboulev V., Ulzheimer J.C., Akhoundova A., Ulzheimer-Teuber I., Karbach U., Quester S., et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 16 (1997) 871-881
13. Urakami Y., Akazawa M., Saito H., Okuda M., and Inui K. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J Am Soc Nephrol 13 (2002) 1703-1710
14. Tsuruoka S., Ishibashi K., Yamamoto H., Wakaumi M., Suzuki M., Schwartz G.J., et al. Functional analysis of ABCA8, a new drug transporter. Biochem Biophys Res Commun 298 (2002) 41-45
15. Koepsell H., and Endou H. The SLC22 drug transporter family. Pflugers Arch 447 (2004) 666-676
16. Chen C., Hanson E., Watson J.W., and Lee J.S. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metab Dispos 31 (2003) 312-318
17. Karyekar C.S., Eddington N.D., Briglia A., Gubbins P.O., and Dowling T.C. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol 44 (2004) 919-927
18. Pan B.F., Dutt A., and Nelson J.A. Enhanced transepithelial flux of cimetidine by Madin-Darby canine kidney cells overexpressing human P-glycoprotein. J Pharmacol Exp Ther 270 (1994) 1-7
19. Cha S.H., Sekine T., Fukushima J.I., Kanai Y., Kobayashi Y., Goya T., et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59 (2001) 1277-1286
20. Wakasugi H., Yano I., Ito T., Hashida T., Futami T., Nohara R., et al. Effect of clarithromycin on renal excretion of digoxin. interaction with P-glycoprotein. Clin Pharmacol Ther 64 (1998) 123-128
21. Horita Y., Kanaya H., Uno Y., Yamazaki T., Kaku B., Funada A., et al. A case of the toxicity of pilsicainide hydrochloride with comparison of the serial serum pilsicainide levels and electrocardiographic findings. Jpn Heart J 45 (2004) 1049-1056
22. Wood S.G., John B.A., Chasseaud L.F., Yeh J., and Chung M. The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann Allergy 59 Pt 2 (1987) 31-34
23. Nakashima M., Kanamaru M., Uematsu T., Ohnuma N., Hayashi T., et al. Phase I study of SUN 1165, a novel antiarrhythmic agent: No.1: single dose study [in Japanese]. J Clin Ther Med 5 (1989) 661-678